Bladder Cancer Update & Renal Cell Cancer Update, 2017 (Video Program)


Activity and tolerability of the recently FDA-approved anti-PD-L1 antibody atezolizumab for advanced UBC
4:38 minutes.

BLADDER CANCER
(Neo)adjuvant treatment for urothelial bladder cancer (UBC)

Therapeutic options for patients with advanced UBC

Immune checkpoint blockade in UBC

RENAL CELL CANCER
Adjuvant sorafenib or sunitinib for renal cell carcinoma (RCC)

Selection and sequencing of therapeutic options for advanced RCC

Immune checkpoint blockade in RCC